Karin bayani ― Hausa

An san Laser ɗin Q-switched Nd:YAG don magance nevus na Ota yadda ya kamata da makamantansu. Mun gudanar da bincike don ganin yadda na'urar laser high-fluence 1064 nm Q-switched Nd:YAG ta yi aiki a wuraren Mongolian a wuraren da ba a saba gani ba, ba tare da sanya fata ta yi haske ba. Mun yi nazarin marasa lafiya 61 tare da waɗannan aibobi, muna nazarin jimillar raunuka 70. An yi amfani da rabi na raunuka tare da laser, yayin da wasu ba a kula da su ba don kwatantawa. Mun kimanta sakamakon ta amfani da sikeli da na'urar da ake kira Mexameter® don auna matakan melanin. An bi marasa lafiya na tsawon watanni 14 a cikin ƙungiyar kulawa da watanni 18 a cikin ƙungiyar kulawa. A ƙarshen binciken, mun sami bambance-bambance masu mahimmanci a cikin ma'auni da matakan melanin tsakanin ƙungiyoyin da aka bi da su da marasa lafiya, tare da ƙungiyar da aka yi amfani da laser suna nuna sakamako mafi kyau. Laser na high-fluence Q-switched Nd:YAG , ba tare da haifar da walƙiyar fata ba, ya tabbatar da inganci da aminci don magance waɗannan wuraren da ba a saba gani ba na Mongolian.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

Mun yi nazarin tasiri da amincin amfani da takamaiman magani na Laser don ABNOM , kuma mun kalli abubuwan da za su iya shafar yadda yake aiki sosai. Mun duba marasa lafiya 110 da suka sami ABNOM kuma sun sami tsakanin jiyya biyu zuwa tara. Mun gano cewa maganin ya yi aiki mafi kyau tsawon lokacin da aka yi shi, amma ba kamar yadda a cikin tsofaffin marasa lafiya ba. Har ila yau, ya yi aiki mafi kyau a marasa lafiya tare da fata mai laushi (nau'in III) da ƙananan wuraren da aka shafa (kasa da 10 cm2) . Samun melasma tare da ABNOM ya sa maganin ba shi da tasiri. Launi ko adadin wuraren da abin ya shafa bai yi wani tasiri ba. Kusan kashi 10 cikin 100 na marasa lafiya sun sami tabo masu duhu bayan jiyya. Magani da yawa na farko ya ba da sakamako mai kyau. Tsofaffin majinyata masu duhun fata da tabo masu duhu suna iya samun tabo mai duhu bayan jiyya. Ga marasa lafiya da ABNOM da ciwon ciki, yana da kyau a yi amfani da Laser mai ƙarancin kuzari don guje wa cutar da ciwon.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.